AARTIDRUGS

Aarti Drugs Share PriceAarti Drugs

₹471.15
11.15 (2.42%)
As on 08 June, 2023 | 03:22 BSE: 524348 NSE: AARTIDRUGS

Aarti Drugs Performance

Day Range

  • Low
  • High
471.15

52 Week Range

  • Low
  • High
471.15
  • Open Price
  • Previous Close
  • Volume

Start SIP in Aarti Drugs

Start SIP

Aarti Drugs Share Price

  • Over 1 Month 5.7%
  • Over 3 Month 31.2%
  • Over 6 Month 3.09%
  • Over 1 Year 11.82%

Aarti Drugs Key Statistics

P/E Ratio 26.2
PEG Ratio -1.4
Market Cap Cr 4,363
Price to Book Ratio 3.7
EPS 16.5
Dividend 0.2
Relative Strength Index 62.4
Money Flow Index 76.49
MACD Signal 8.6
Average True Range 16.3

Aarti Drugs Investment Rating

  • Master Rating:
  • Aarti Drugs has an operating revenue of Rs. 2,716.05 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 8% is okay, ROE of 13% is good. The company has a reasonable debt to equity of 17%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 6% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 8% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 111 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Aarti Drugs Financials
IndicatorMar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 696626625551641
Operating Expenses Qtr Cr 608557555496557
Operating Profit Qtr Cr 8969705584
Depreciation Qtr Cr 1212121212
Interest Qtr Cr 89876
Tax Qtr Cr 1612141014
Net Profit Qtr Cr 5337372653

Aarti Drugs Technicals

EMA & SMA

Current Price
₹471.15
11.15 (2.42%)
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹452.16
  • 50 Day
  • ₹433.86
  • 100 Day
  • ₹424.49
  • 200 Day
  • ₹431.88
  • 20 Day
  • ₹455.69
  • 50 Day
  • ₹426.91
  • 100 Day
  • ₹406.83
  • 200 Day
  • ₹432.08

Aarti Drugs Resistance and Support

PIVOT
₹463.49
Resistance
First Resistance ₹469.97
Second Resistance ₹479.94
Third Resistance ₹486.42
RSI 62.4
MFI 76.49
MACD Single Line 8.6
MACD 8.42
Support
First Resistance ₹453.52
Second Resistance ₹447.04
Third Resistance ₹437.07

Aarti Drugs Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 599,566 23,760,801 39.63
Week 488,237 13,631,577 27.92
1 Month 316,340 8,284,954 26.19
6 Month 572,450 6,880,847 12.02

Aarti Drugs Result Highlights

Aarti Drugs Synopsis

NSE-Medical-Diversified

Aarti Drugs Ltd is involved in the business activities of Manufacture of basic chemicals, fertilizer and nitrogen compounds, plastics and synthetic rubber in primary forms. Company’s Total Operating Revenue is Rs. 2497.97 Cr. and Equity Capital is Rs. 92.60 Cr. for the Year ended 31/03/2023. Aarti Drugs Ltd. is a Public Limited Listed company incorporated on 28/09/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L37060MH1984PLC055433 and registration number is 055433.
Market Cap 4,363
Sales 2,498
Shares in Float 3.70
No of funds 73
Yield 0.21
Book Value 3.92
U/D Vol ratio 1
LTDebt / Equity 15
Alpha 0.05
Beta 0.56

Aarti Drugs

Owner NameMar-23Dec-22Sep-22Jun-22
Promoters 59.58%59.66%59.77%59.98%
Mutual Funds 4.01%3.82%3.08%2.68%
Insurance Companies 0.08%0.08%0.08%0.08%
Foreign Portfolio Investors 1.94%1.9%1.94%2.07%
Financial Institutions/ Banks
Individual Investors 25.72%25.98%26.66%32.16%
Others 8.67%8.56%8.47%3.03%

Aarti Drugs Management

Name Designation
Mr. Chandrakant V Gogri Chairman Emeritus
Mr. Prakash M Patil Chairman & M.D & CEO
Mr. Rashesh C Gogri Managing Director
Mr. Harshit M Savla Joint Managing Director
Mr. Harit P Shah Executive Director
Mr. Uday M Patil Executive Director
Mr. Neha R Gada Non Executive Director
CA. Navin C Shah Independent Director
Dr. Krishnacharya G Akamanchi Independent Director
Prof. Bhaskar N Thorat Independent Director
CA. Priti P Savla Independent Director

Aarti Drugs Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Aarti Drugs Corporate Action

Date Purpose Remarks
2023-04-29 Audited Results
2023-01-27 Quarterly Results & Interim Dividend
2022-10-20 Quarterly Results
2022-07-27 Quarterly Results
2022-05-09 Audited Results
Date Purpose Remarks
2023-02-08 INTERIM Rs.1.00 per share(10%)Interim Dividend
2022-02-10 INTERIM Rs.1.00 per share(10%)Interim Dividend

Aarti Drugs MF Shareholding

Name Amount(cr)
DSP Small Cap Fund Regular Plan Growth 9409
DSP Healthcare Fund Regular Growth 1243
DSP Value Fund Regular Plan Growth 606
Nippon India Nifty Smallcap 250 Index Fund Reg Gr 428
Motilal Oswal Nifty 500 Fund Regular Growth 418

Aarti Drugs FAQs

What is Share Price of Aarti Drugs ?

Aarti Drugs share price is ₹471 As on 08 June, 2023 | 03:08

What is the Market Cap of Aarti Drugs ?

The Market Cap of Aarti Drugs is ₹4362.8 Cr As on 08 June, 2023 | 03:08

What is the P/E ratio of Aarti Drugs ?

The P/E ratio of Aarti Drugs is 26.2 As on 08 June, 2023 | 03:08

What is the PB ratio of Aarti Drugs ?

The PB ratio of Aarti Drugs is 3.7 As on 08 June, 2023 | 03:08

Q2FY23

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number